- Home
- BKH vs GH Comparison
BKH vs GH Comparison
Compare BKH & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BKH | GH |
|---|---|---|
| Founded | 1941 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Medical Specialities |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 14.1B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | BKH | GH |
|---|---|---|
| Price | $69.60 | $102.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 21 |
| Target Price | $71.00 | ★ $96.48 |
| AVG Volume (30 Days) | 914.1K | ★ 1.8M |
| Earning Date | 02-04-2026 | 02-19-2026 |
| Dividend Yield | ★ 3.88% | N/A |
| EPS Growth | ★ 7.21 | N/A |
| EPS | ★ 3.95 | N/A |
| Revenue | ★ $2,271,600,000.00 | $902,569,000.00 |
| Revenue This Year | $10.35 | $35.00 |
| Revenue Next Year | $3.07 | $26.80 |
| P/E Ratio | $17.64 | ★ N/A |
| Revenue Growth | 7.04 | ★ 30.38 |
| 52 Week Low | $54.92 | $30.97 |
| 52 Week High | $74.02 | $112.43 |
Technical Indicators
Market Signals| Indicator | BKH | GH |
|---|---|---|
| Relative Strength Index (RSI) | 49.26 | 53.59 |
| Support Level | $69.33 | $99.82 |
| Resistance Level | $70.14 | $104.75 |
| Average True Range (ATR) | 1.31 | 3.05 |
| MACD | -0.20 | -0.51 |
| Stochastic Oscillator | 39.90 | 62.54 |
Price Performance
Historical ComparisonAbout BKH Black Hills Corporation
Black Hills Corp is a U.S.-based energy company that operates through its Electric Utilities and Gas Utilities segment. These segments operate in states in the Midwest and mountain regions in the U.S. The company's customers include residential, commercial, industrial, and municipal consumers. These customers are residential. Black Hills derives the majority of its revenue from its utility business group, specifically from gas utilities.
About GH Guardant Health Inc.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.